Search results
Results from the WOW.Com Content Network
In "Beetlejuice Beetlejuice," Delia Deetz (Catherine O'Hara), Lydia Deetz (Winona Ryder) and Lydia's daughter Astrid (Jenna Ortega) return to the fictional town of Winter River after a family tragedy.
In "Beetlejuice Beetlejuice," Blundell said that she and animatronic and special makeup effects supervisor Neal Scanlan worked together to craft a quick mask with yellow-painted ping-pong balls to ...
Beetlejuice opened theatrically in the United States on March 30, 1988, earning $8,030,897 its opening weekend, which at the time, was an Easter weekend record. The film eventually grossed $75.1 million worldwide. Beetlejuice was a financial success, [28] recouping its $15 million budget and becoming the 10th-highest-grossing film of 1988. [29 ...
Frequency. ~25% in any given month [ 7 ][ 8 ] Low back pain or lumbago is a common disorder involving the muscles, nerves, and bones of the back, in between the lower edge of the ribs and the lower fold of the buttocks. Pain can vary from a dull constant ache to a sudden sharp feeling. [ 4 ]
Beetlejuice Beetlejuice is a 2024 American dark fantasy comedy horror film directed by Tim Burton from a screenplay by Alfred Gough and Miles Millar.A sequel to Beetlejuice (1988) and the second film of the Beetlejuice franchise, the film stars Michael Keaton, Winona Ryder, and Catherine O'Hara reprising their roles alongside new cast members Justin Theroux, Monica Bellucci, Jenna Ortega, and ...
For premium support please call: 800-290-4726 more ways to reach us
Spinal manipulation appears to provide similar effects to other recommended treatments for chronic low back pain. [57] There is no evidence it is more effective than other therapies or sham, or as an adjunct to other treatments, for acute low back pain [58] "Back school" is an intervention that consists of both education and physical exercises.
Rofecoxib is a COX-2-selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. Rofecoxib was approved in the US by the US Food and Drug Administration (FDA) in May 1999, and was marketed ...